In this session, first recorded at the 2022 IO360° Summit, Dr Semenza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include:

Regions of intratumoral hypoxia are a common feature of advanced cancers
Hypoxia-inducible factors increase the expression of multiple proteins that mediate immune evasion
HIF inhibitors stimulate anti-tumor immunity and improve the response to immune checkpoint blockade

Gregg Semenza, MD, PhD, Director, Vascular Program, Institute for Cell Engineering and Professor of Genetic Medicine, Johns Hopkins University School of Medicine

Learn more about the IO360° Summit at www.io360summit.com

Mechanisms of Immune Evasion Mediated by Hypoxia- Inducible Factors

Share

Embed